+$213.0M
Net Activity
Institutions Holding
162
Popularity Rank
#3399
Avg Weight
0.06%
Total Value
$213.0M
162 institutions currently hold RNA, with 159 net buyers and 0 net sellers this quarter.
Institutional Moves (Q1 2026)
Significantly Increased
Based on recent trading activity
Net Selling Institutions
0
Net Buying Institutions
159
Top 5 by Value
+$192.4M
Total Buy Value
$0.0
Total Sell Value
159
Net Buyers
0
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Atrium Therapeutics (RNA) announced that the FDA cleared its Investigational New Drug application for ATR 1072. This clearance allows the company to begin a Phase 1/2 clinical trial for PRKAG2 syndrome, a rare genetic heart condition. The trial, named Corventis, will evaluate the drug's safety and effectiveness.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter